<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82374">
  <stage>Registered</stage>
  <submitdate>24/10/2007</submitdate>
  <approvaldate>20/12/2007</approvaldate>
  <actrnumber>ACTRN12607000651482</actrnumber>
  <trial_identification>
    <studytitle>Nutritional polypill trial in well subjects in order to assess genome damage</studytitle>
    <scientifictitle>A polypill vs placebo trial to assess genome damage in well subjects</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Damage in lymphocyte deoxyribonucleic acid (DNA)</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intervention: 2 small tablets + 1 capsule, taken simultaneously, daily, orally; Contents: vitamins (B12, E, A, B3) and essential nutrients (folate, calcium); Duration: 16 weeks; 
Exposure: lifestyle, ageing, nutrition practices.</interventions>
    <comparator>2 small tablets + 1 capsule, tablets and capsule taken daily (sugar pills).</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Micronucleus (MN) frequency in lymphocytes assessed by visual scoring.</outcome>
      <timepoint>3 x 16 week phases with active &amp; placebo interventions ocurring in 2nd and 3rd phases</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Global methylation of DNA and CpG island (DNA stretch where higher frequency of C-G pairs is observed).</outcome>
      <timepoint>16, 32 and 48 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>25 - 45 year-old healthy males and females.</inclusivecriteria>
    <inclusiveminage>25</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Subjects who smoke, are currently being treated with anti-folate drugs, are planning a pregnancy or are currently pregnant, are unable to participate in all phases of the trial, or are supplementing their diet with more than 50% of the recommended daily dietary allowance (RDA) of any nutrients identified for the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Treatment codes generated by independent allocation; only subject and bottle numbers are available at registration; dispensing bottles and contents are identical in apprearance for both treatment and active groups;</concealment>
    <sequence>Treatment sequence was generated by stratified (tertiles of age, sex of volunteers obtained from phase 1), randomised blocks of size 4, with each block containing 2 placebo and two active treatment allocations.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/10/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>250</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>5000</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>NHMRC</primarysponsorname>
    <primarysponsoraddress>Canberra ACT</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council (NHMRC)</fundingname>
      <fundingaddress>Canberra ACT</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>NHMRC</sponsorname>
      <sponsoraddress>Canberra ACT</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study investigates the potential benefit of supplementary vitamins and essential minerals in the prevention of breaks in cellular DNA, which are associated with cancer development.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Sydney Human Research Ethics Committee</ethicname>
      <ethicaddress>University of Sydney
Camperdown NSW 2006</ethicaddress>
      <ethicapprovaldate>28/05/2007</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Bruce Armstrong</name>
      <address>Sydney Cancer Centre
Gloucester House
Royal Prince Alfred Hospital
Sydney NSW</address>
      <phone>+61 2 95157069</phone>
      <fax />
      <email>brucea@health.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Bruce Armstrong</name>
      <address>Sydney Cancer Centre
Gloucester House
Royal Prince Alfred Hospital
Sydney NSW</address>
      <phone>+61 2 95157069</phone>
      <fax />
      <email>brucea@health.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Patrick FitzGerald</name>
      <address>NHMRC Clinical Trials Centre
88 Mallett St
Camperdown NSW 2050</address>
      <phone />
      <fax />
      <email>pfitzgerald@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>